215 related articles for article (PubMed ID: 36421662)
21. Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens.
Moore SC; Kronsteiner B; Longet S; Adele S; Deeks AS; Liu C; Dejnirattisai W; Reyes LS; Meardon N; Faustini S; Al-Taei S; Tipton T; Hering LM; Angyal A; Brown R; Nicols AR; Dobson SL; Supasa P; Tuekprakhon A; Cross A; Tyerman JK; Hornsby H; Grouneva I; Plowright M; Zhang P; Newman TAH; Nell JM; Abraham P; Ali M; Malone T; Neale I; Phillips E; Wilson JD; Murray SM; Zewdie M; Shields A; Horner EC; Booth LH; Stafford L; Bibi S; Wootton DG; Mentzer AJ; Conlon CP; Jeffery K; Matthews PC; Pollard AJ; Brown A; Rowland-Jones SL; Mongkolsapaya J; Payne RP; Dold C; Lambe T; Thaventhiran JED; Screaton G; Barnes E; Hopkins S; Hall V; Duncan CJA; Richter A; Carroll M; de Silva TI; Klenerman P; Dunachie S; Turtle L;
Med; 2023 Mar; 4(3):191-215.e9. PubMed ID: 36863347
[TBL] [Abstract][Full Text] [Related]
22. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL
PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890
[TBL] [Abstract][Full Text] [Related]
23. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
24. Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2.
Ukey R; Bruiners N; Mishra H; Mishra PK; McCloskey D; Onyuka A; Chen F; Pinter A; Weiskopf D; Sette A; Roy J; Gaur S; Gennaro ML
BMC Med; 2022 Jan; 20(1):32. PubMed ID: 35073931
[TBL] [Abstract][Full Text] [Related]
25. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters.
Machado RRG; Walker JL; Scharton D; Rafael GH; Mitchell BM; Reyna RA; de Souza WM; Liu J; Walker DH; Plante JA; Plante KS; Weaver SC
Nat Commun; 2023 Jul; 14(1):4260. PubMed ID: 37460536
[TBL] [Abstract][Full Text] [Related]
27. Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals.
Dai YC; Lin YC; Ching LL; Tsai JJ; Ishikawa K; Tsai WY; Chen JJ; Nerurkar VR; Wang WK
Microbiol Spectr; 2023 Aug; 11(4):e0408122. PubMed ID: 37428104
[TBL] [Abstract][Full Text] [Related]
28. Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines.
Kaplonek P; Deng Y; Shih-Lu Lee J; Zar HJ; Zavadska D; Johnson M; Lauffenburger DA; Goldblatt D; Alter G
Cell Rep Med; 2023 May; 4(5):101048. PubMed ID: 37182520
[TBL] [Abstract][Full Text] [Related]
29. Durability of Heterologous and Homologous COVID-19 Vaccine Boosts.
Tan CS; Collier AY; Yu J; Liu J; Chandrashekar A; McMahan K; Jacob-Dolan C; He X; Roy V; Hauser BM; Munt JE; Mallory ML; Mattocks M; Powers JM; Meganck RM; Rowe M; Hemond R; Bondzie EA; Jaegle KH; Baric RS; Schmidt AG; Alter G; Le Gars M; Sadoff J; Barouch DH
JAMA Netw Open; 2022 Aug; 5(8):e2226335. PubMed ID: 35947380
[TBL] [Abstract][Full Text] [Related]
30. Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.
Cho A; Muecksch F; Wang Z; Ben Tanfous T; DaSilva J; Raspe R; Johnson B; Bednarski E; Ramos V; Schaefer-Babajew D; Shimeliovich I; Dizon JP; Yao KH; Schmidt F; Millard KG; Turroja M; Jankovic M; Oliveira TY; Gazumyan A; Gaebler C; Caskey M; Hatziioannou T; Bieniasz PD; Nussenzweig MC
J Exp Med; 2022 Aug; 219(8):. PubMed ID: 35776090
[TBL] [Abstract][Full Text] [Related]
31. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
Front Immunol; 2022; 13():909910. PubMed ID: 35784321
[TBL] [Abstract][Full Text] [Related]
32. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
[TBL] [Abstract][Full Text] [Related]
33. Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine.
Schmidt KG; Harrer EG; Schönau V; Simon D; Kleyer A; Steininger P; Korn K; Schett G; Knobloch CS; Nganou-Makamdop K; Harrer T
Infection; 2023 Dec; 51(6):1657-1667. PubMed ID: 37067754
[TBL] [Abstract][Full Text] [Related]
34. Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany.
Dulovic A; Kessel B; Harries M; Becker M; Ortmann J; Griesbaum J; Jüngling J; Junker D; Hernandez P; Gornyk D; Glöckner S; Melhorn V; Castell S; Heise JK; Kemmling Y; Tonn T; Frank K; Illig T; Klopp N; Warikoo N; Rath A; Suckel C; Marzian AU; Grupe N; Kaiser PD; Traenkle B; Rothbauer U; Kerrinnes T; Krause G; Lange B; Schneiderhan-Marra N; Strengert M
Front Immunol; 2022; 13():828053. PubMed ID: 35251012
[TBL] [Abstract][Full Text] [Related]
35. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX).
Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J
Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050
[TBL] [Abstract][Full Text] [Related]
36. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses.
Almendro-Vázquez P; Chivite-Lacaba M; Utrero-Rico A; González-Cuadrado C; Laguna-Goya R; Moreno-Batanero M; Sánchez-Paz L; Luczkowiak J; Labiod N; Folgueira MD; Delgado R; Paz-Artal E
Front Immunol; 2022; 13():981350. PubMed ID: 36059485
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea.
Widyasari K; Jang J; Lee S; Kang T; Kim S
J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 1):1013-1024. PubMed ID: 36261313
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccine.
Le Gars M; Hendriks J; Sadoff J; Ryser M; Struyf F; Douoguih M; Schuitemaker H
Immunol Rev; 2022 Sep; 310(1):47-60. PubMed ID: 35689434
[TBL] [Abstract][Full Text] [Related]
39. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
Yang LM; Costales C; Ramanathan M; Bulterys PL; Murugesan K; Schroers-Martin J; Alizadeh AA; Boyd SD; Brown JM; Nadeau KC; Nadimpalli SS; Wang AX; Busque S; Pinsky BA; Banaei N
J Clin Virol; 2022 Aug; 153():105217. PubMed ID: 35714462
[TBL] [Abstract][Full Text] [Related]
40. Role of COVID-19 Vaccines in SARS-CoV-2 Variants.
Zhou Z; Zhu Y; Chu M
Front Immunol; 2022; 13():898192. PubMed ID: 35669787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
